Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has secured Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug eRapa, a proprietary encapsulated form of rapamycin, for the treatment of familial adenomatous polyposis (FAP). This designation is designed to accelerate the development and review process for drugs that address serious conditions with […]